Literature DB >> 11689644

Porcine encephalomyocarditis virus persists in pig myocardium and infects human myocardial cells.

L A Brewer1, H C Lwamba, M P Murtaugh, A C Palmenberg, C Brown, M K Njenga.   

Abstract

Recent advances toward using pig tissues in human transplantation have made it necessary to determine the risk of transmitting zoonotic viruses from pigs to humans or vice versa. We investigated the suitability of the porcine encephalomyocarditis virus (EMCV) model for such studies by determining its ability to persist in pigs, escape detection by routine serological methods, and infect human cells. Intraperitoneal inoculation of 5-week-old pigs with EMCV-30, a strain isolated from commercial pigs, resulted in acute cellular degeneration, infiltration of lymphocytes, and apoptosis in myocardium in 13 of 15 (86.7%) pigs during the acute phase of disease (3 to 21 days postinfection), followed by less-severe lymphocytic infiltration and apoptosis in 5 of 10 (50%) pigs during the chronic phase of the disease (day 45 to 90 postinfection). In the brain, lymphocytic infiltration, neuronal degeneration, and gliosis were observed in 26 to 33% of pigs in the acute phase of disease whereas perivascular cuffing was the predominant feature during chronic disease. EMCV antigens and RNA were demonstrated in the myocardium and brain during the chronic phase of disease. Analysis of 100 commercial pigs that were negative for EMCV antibodies identified two pig hearts positive for EMCV RNA. Porcine EMCV productively infected primary human cardiomyocytes as demonstrated by immunostaining using a monoclonal antibody specific for EMCV RNA polymerase, which is expressed only in productively infected cells, and by a one-step growth curve that showed production of 100 to 1,000 PFU of virus per cell within 6 h. The findings that porcine EMCV can persist in pig myocardium and can infect human myocardial cells make it an important infectious agent to screen for in pig-to-human cardiac transplants and a good model for xenozoonosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689644      PMCID: PMC114749          DOI: 10.1128/JVI.75.23.11621-11629.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Association of viral genome with graft loss in children after cardiac transplantation.

Authors:  G S Shirali; J Ni; R E Chinnock; J K Johnston; G L Rosenthal; N E Bowles; J A Towbin
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

2.  Specific serum antibodies to infectious disease agents in Tarahumara Indian adolescents of northwestern Mexico.

Authors:  D C GAJDUSEK; N G ROGERS
Journal:  Pediatrics       Date:  1955-12       Impact factor: 7.124

Review 3.  The clinical application of cell grafting techniques in patients with Parkinson's disease.

Authors:  N P Quinn
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

4.  The prevalence of encephalomyocarditis virus neutralizing antibodies among various human populations.

Authors:  R B Tesh
Journal:  Am J Trop Med Hyg       Date:  1978-01       Impact factor: 2.345

5.  Haemagglutination-inhibition antibodies to encephalomyocarditis virus in Queensland cattle.

Authors:  P B Spradbrow; Y S Chung
Journal:  Aust Vet J       Date:  1970-04       Impact factor: 1.281

6.  Encephalomyocarditis virus infections in Florida, 1960-1966.

Authors:  J H Gainer
Journal:  J Am Vet Med Assoc       Date:  1967-08-15       Impact factor: 1.936

7.  Theiler's virus antigen detected in mouse spinal cord 2 1/2 years after infection.

Authors:  H L Lipton; J Kratochvil; P Sethi; M C Dal Canto
Journal:  Neurology       Date:  1984-08       Impact factor: 9.910

8.  Encephalomyocarditis virus disease of pigs associated with a plague of rodents.

Authors:  J T Seaman; J G Boulton; M J Carrigan
Journal:  Aust Vet J       Date:  1986-09       Impact factor: 1.281

Review 9.  Mechanical circulatory support for patients with acute-fulminant myocarditis.

Authors:  M A Acker
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

10.  Device and patient management in a bridge-to-transplant setting.

Authors:  A El-Banayosy; R Körfer; L Arusoglu; L Kizner; M Morshuis; H Milting; G Tenderich; O Fey; K Minami
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

View more
  12 in total

1.  Adaptive Immune Responses following Senecavirus A Infection in Pigs.

Authors:  Mayara F Maggioli; Steve Lawson; Marcelo de Lima; Lok R Joshi; Tatiane C Faccin; Fernando V Bauermann; Diego G Diel
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

2.  Encephalomyocarditis virus 2A protein is required for viral pathogenesis and inhibition of apoptosis.

Authors:  M Carocci; N Cordonnier; H Huet; A Romey; A Relmy; K Gorna; S Blaise-Boisseau; S Zientara; L Bakkali Kassimi
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

3.  A wild-type porcine encephalomyocarditis virus containing a short poly(C) tract is pathogenic to mice, pigs, and cynomolgus macaques.

Authors:  Rebecca LaRue; Suzanne Myers; Laurie Brewer; Daniel P Shaw; Corrie Brown; Bruce S Seal; M Kariuki Njenga
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Pathogenesis of coxsackievirus-B5 acquired from intra-renal porcine islet cell xenografts in diabetic mice.

Authors:  Suzanne E Myers; Rebecca LaRue; Daniel P Shaw; Brenda C Love; Kariuki Njenga M; Moses K Njenga
Journal:  Xenotransplantation       Date:  2009 Mar-Apr       Impact factor: 3.907

5.  Antiapoptotic activity of the cardiovirus leader protein, a viral "security" protein.

Authors:  Lyudmila I Romanova; Peter V Lidsky; Marina S Kolesnikova; Ksenia V Fominykh; Anatoly P Gmyl; Eugene V Sheval; Stanleyson V Hato; Frank J M van Kuppeveld; Vadim I Agol
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

6.  Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.

Authors:  Frederik C Roos; Andrew M Roberts; Irene I L Hwang; Eduardo H Moriyama; Andrew J Evans; Stephanie Sybingco; Ian R Watson; Leticia A M Carneiro; Craig Gedye; Stephen E Girardin; Laurie E Ailles; Michael A S Jewett; Michael Milosevic; Brian C Wilson; John C Bell; Sandy D Der; Michael Ohh
Journal:  EMBO Mol Med       Date:  2010-07       Impact factor: 12.137

7.  Clinical problems due to encephalomyocarditis virus infections in two pig herds.

Authors:  Klaas Vansteenkiste; Tommy Van Limbergen; Ruben Decaluwé; Marylène Tignon; Brigitte Cay; Dominiek Maes
Journal:  Porcine Health Manag       Date:  2016-08-07

8.  Transcriptional profiling of host cell responses to encephalomyocarditis virus (EMCV).

Authors:  Jia Wei; Haixia Zhang; Xiangrong Li; Qiongyi Li; Zhongren Ma; Jialin Bai; Zilin Qiao; Ruofei Feng
Journal:  Virol J       Date:  2017-03-04       Impact factor: 4.099

9.  The Origin, Dynamic Morphology, and PI4P-Independent Formation of Encephalomyocarditis Virus Replication Organelles.

Authors:  F J M van Kuppeveld; M Bárcena; C E Melia; H M van der Schaar; A W M de Jong; H R Lyoo; E J Snijder; A J Koster
Journal:  MBio       Date:  2018-04-17       Impact factor: 7.867

10.  Higher Concentration of Hypertonic Saline Shows Better Recovery Effects on Rabbits with Uncontrolled Hemorrhagic Shock.

Authors:  Lei Xu; Fengjuan Kang; Wendong Hu; Xiwen Liu
Journal:  Med Sci Monit       Date:  2019-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.